English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Molecular-targeting therapeutics directed towards growth factor receptors have become promising interventions in cancer. They include the family of mammalian receptor tyrosine kinases such as epidermal growth factor, nerve growth factor TrkA and insulin. In particular, the insulin receptor (IR) is one of the most well-known members of the RTK family of receptors playing a role in cancer. IRs are covalently-linked heterodimers of ab subunits on the cell membrane in the absence of insulin binding. The IR signalling pathways are initially triggered by insulin binding to the extracellular portion of a subunits followed by the interaction of b subunits and ATP. The parameter(s) controlling insulin-induced conformational change of the receptor and activation remains unknown.

bmc genomics

Neu1 sialidase and matrix metalloproteinase-9 cross-talk in alliance with insulin receptors is an essential molecular signaling platform for insulin-induced receptor activation